Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer

• Үндсэн зохиолчид: Milene Volpato (Зохиогч), Michele Cummings (Зохиогч), Abeer M. Shaaban (Зохиогч), Balkees Abderrahman (Зохиогч), Mark A. Hull (Зохиогч), Philipp Y. Maximov (Зохиогч), Bradley M. Broom (Зохиогч), Reiner Hoppe (Зохиогч), Ping Fan (Зохиогч), Hiltrud Brauch (Зохиогч), V. Craig Jordan (Зохиогч), Valerie Speirs (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Open Exploration Publishing Inc., 2020-10-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Aim: Tamoxifen (TAM) resistance remains a clinical issue in breast cancer. The authors previously reported that 15-hydroxyprostaglandin dehydrogenase (HPGD) was significantly downregulated in tamoxifen-resistant (TAMr) breast cancer cell lines. Here, the authors investigated the relationship between...